167 related articles for article (PubMed ID: 26350593)
1. Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).
Overholser J; Ambegaokar KH; Eze SM; Sanabria-Figueroa E; Nahta R; Bekaii-Saab T; Kaumaya PT
Vaccines (Basel); 2015 Jul; 3(3):519-43. PubMed ID: 26350593
[TBL] [Abstract][Full Text] [Related]
2. IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.
Foy KC; Miller MJ; Overholser J; Donnelly SM; Nahta R; Kaumaya PT
Oncoimmunology; 2014 Nov; 3(11):e956005. PubMed ID: 25941587
[TBL] [Abstract][Full Text] [Related]
3. HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.
Miller MJ; Foy KC; Overholser JP; Nahta R; Kaumaya PT
Oncoimmunology; 2014 Nov; 3(11):e956012. PubMed ID: 25941588
[TBL] [Abstract][Full Text] [Related]
4. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.
Kaumaya PT
Hum Vaccin Immunother; 2015; 11(6):1368-86. PubMed ID: 25874884
[TBL] [Abstract][Full Text] [Related]
5. Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells.
Wu W; Ma J; Shao N; Shi Y; Liu R; Li W; Lin Y; Wang S
PLoS One; 2017; 12(1):e0169229. PubMed ID: 28046018
[TBL] [Abstract][Full Text] [Related]
6. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.
Terwisscha van Scheltinga AG; Berghuis P; Nienhuis HH; Timmer-Bosscha H; Pot L; Gaykema SB; Lub-de Hooge MN; Kosterink JG; de Vries EG; Schröder CP
Eur J Cancer; 2014 Sep; 50(14):2508-16. PubMed ID: 25027745
[TBL] [Abstract][Full Text] [Related]
7. XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.
Schanzer JM; Wartha K; Moessner E; Hosse RJ; Moser S; Croasdale R; Trochanowska H; Shao C; Wang P; Shi L; Weinzierl T; Rieder N; Bacac M; Ries CH; Kettenberger H; Schlothauer T; Friess T; Umana P; Klein C
MAbs; 2016; 8(4):811-27. PubMed ID: 26984378
[TBL] [Abstract][Full Text] [Related]
8. Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line.
Ayub A; Yip WK; Seow HF
Biomed Pharmacother; 2015 Oct; 75():40-50. PubMed ID: 26463630
[TBL] [Abstract][Full Text] [Related]
9. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment.
Obr AE; Kumar S; Chang YJ; Bulatowicz JJ; Barnes BJ; Birge RB; Lazzarino DA; Gallagher E; LeRoith D; Wood TL
Breast Cancer Res; 2018 Nov; 20(1):138. PubMed ID: 30458886
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
12. Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells.
Liu CY; Chu PY; Huang CT; Chen JL; Yang HP; Wang WL; Lau KY; Lee CH; Lan TY; Huang TT; Lin PH; Dai MS; Tseng LM
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30658422
[TBL] [Abstract][Full Text] [Related]
13. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.
Foy KC; Miller MJ; Moldovan N; Carson WE; Kaumaya PT
Oncoimmunology; 2012 Oct; 1(7):1048-1060. PubMed ID: 23170253
[TBL] [Abstract][Full Text] [Related]
14. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines.
Stanley A; Ashrafi GH; Seddon AM; Modjtahedi H
Sci Rep; 2017 Jun; 7(1):3964. PubMed ID: 28638122
[TBL] [Abstract][Full Text] [Related]
16.
Solomon VR; Alizadeh E; Bernhard W; Hartimath SV; Hill W; Chekol R; Barreto KM; Geyer CR; Fonge H
Mol Pharm; 2019 Dec; 16(12):4807-4816. PubMed ID: 31518138
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
18. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.
Lanning NJ; Castle JP; Singh SJ; Leon AN; Tovar EA; Sanghera A; MacKeigan JP; Filipp FV; Graveel CR
Cancer Metab; 2017; 5():6. PubMed ID: 28852500
[TBL] [Abstract][Full Text] [Related]
19. Anti-Cancer Effects of an Optimised Combination of Ginsenoside Rg3 Epimers on Triple Negative Breast Cancer Models.
Nakhjavani M; Smith E; Palethorpe HM; Tomita Y; Yeo K; Price TJ; Townsend AR; Hardingham JE
Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34208799
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.
Köstler WJ; Hudelist G; Rabitsch W; Czerwenka K; Müller R; Singer CF; Zielinski CC
J Cancer Res Clin Oncol; 2006 Jan; 132(1):9-18. PubMed ID: 16184380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]